‘MARKED IMPROVEMENT’ FOR TISSUE THERAPIES’ 1st PATIENT
September 4th 2008 21:43
Wednesday September 3, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: STEM CELL UP 25%, POLARTECHNICS DOWN 19%
* ‘MARKED IMPROVEMENT’ FOR TISSUE THERAPIES’ 1st PATIENT
* ISRAEL APPROVES ANADIS CANCER-RELATED MUCOSITIS TRIAL
* SPINIFEX RAISES $12m FOR PAIN RESEARCH
* NEURODISCOVERY WINS $170k RESEARCH CONTRACT
* OCCUPATIONAL & MEDICAL IN $3m SOUTH AFRICAN DEAL
* BIO-MELBOURNE WORKSHOP: THE ABC OF BUSINESS DEVELOPMENT
* OPPENHEIMER FUNDS TAKES 20% OF PROTEOME
* MICHAEL SPOONER SELLS MESOBLAST SHARES TO EXERCISE OPTIONS
* DR MEGAN CLARK APPOINTED CSIRO CHIEF EXECUTIVE
* STEM CELL CENTRE TRAINS YOUNG SCIENTISTS
* PEPLIN CEO TOM WIGGANS STARTS ON $US350k; AGM NOTICE
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
TISSUE THERAPIES
Tissue Therapies says the first of eight Perth patients to be treated with Vitrogro for venous ulcers has demonstrated “a marked improvement” with no adverse events.
Tissue Therapies said 70-year old Dot Harrison suffered from a venous ulcer on her right ankle which had not healed with conventional dressings.
The company said that following treatment with Vitrogro “her venous ulcer reduced in area by more than 60 percent in only 21 days, there was a marked improvement in the health of the tissue at the edge of the wound and full healing is expected”.
There were no adverse reactions, the company said.
Tissue Therapies chief executive officer Dr Steven Mercer said while the clinical progress of one patient was not conclusive, the company was “very excited” by the results because this was how it expected Vitrogro to perform clinically.
“There is no doubt that the rapid reduction in ulcer size and improvement in health of the skin in the wound area are highly unusual for a chronic venous ulcer,” Dr Mercer said.
“With the use of Vitrogro, it appears that Mrs Harrison’s ulcer is healing in a way that is exceptional,” Dr Mercer said.
Dr Mercer told Biotech Daily that the remaining seven patients in the Perth trial (see Biotech Daily July 9, 2008) would be treated by the end of December with results by the end of January.
Dr Mercer said progress had been made in the long-delayed Toronto trial and he hoped to have regulatory approval in the coming months.
Tissue Therapies climbed 1.5 cents or 17.65 percent to 10 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 24 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
